文献速递生殖医学妇科

脆性X综合征PGT中获至少一枚可移植健康胚胎的成熟卵母细胞阈值

What is the threshold of mature oocytes to obtain at least one healthy transferable cleavage-stage embryo after preimplantation genetic testing for fragile X syndrome?
PubMed 文献 · Hum Reprod · 2021-01-01

本研究回顾性分析38例FMR1突变女性携带者共95个控制性卵巢刺激周期,并与平衡易位男性伴侣的周期按1:3匹配对照。结果显示,获7枚及以上成熟卵母细胞的周期有83%概率获得至少一枚健康胚胎;取7枚MII卵母细胞时灵敏度82%、特异度61%,取10枚时特异度85%。

要点

  • 获7枚及以上成熟卵母细胞的周期有83%概率获得至少一枚健康胚胎。
  • 7枚MII卵母细胞阈值对应灵敏度82%、特异度61%。
  • 10枚MII卵母细胞阈值对应特异度85%,阳性预测值更优。

核心结论

  • 在本研究人群中,一个周期获7枚及以上成熟卵母细胞时有83%的概率获得一枚或以上健康胚胎。

研究设计与样本

  • 单中心回顾性观察研究,2006年1月至2020年1月,分析38例FMR1突变女性携带者(16例前突变、22例全突变)的95个PGT控制性卵巢刺激周期。
  • 每个FMR1-PGT周期与携带任何类型易位男性的伴侣的控制性卵巢刺激周期按1:3匹配,采用条件逻辑回归比较结局,并用ROC曲线分析估算所需成熟卵母细胞数。
  • 仅纳入年龄≤38岁、抗苗勒管激素(AMH)>1 ng/ml且窦卵泡计数(AFC)>10个卵泡的患者。

主要发现

  • FMR1-PGT组每周期获卵数中位数11枚(四分位距7-15),成熟卵母细胞中位数9枚(6-12)。
  • FMR1前突变或全突变女性携带者的控制性卵巢刺激结局与平衡易位男性伴侣的匹配周期相比无改变。
  • FMR1-PGT组获第3天胚胎中位数6枚(4-10),其中形态学适合活检的胚胎中位数3枚(1-6),最终获得健康胚胎中位数1枚(1-3)。
  • 7枚MII卵母细胞 cut-off 值对应获至少一枚健康胚胎的灵敏度82%、特异度61%;10枚MII卵母细胞 cut-off 值对应特异度85%并改善阳性预测值。

关键数值与推荐

  • 7枚MII卵母细胞:灵敏度82%,特异度61%,对应获至少一枚健康胚胎的概率83%。
  • 10枚MII卵母细胞:特异度85%,阳性预测值改善。

临床怎么用

  • 对于AMH>1 ng/ml且AFC>10个卵泡的FMR1突变女性携带者,可参考7枚成熟卵母细胞作为获至少一枚健康胚胎的阈值进行咨询。
  • 获10枚及以上成熟卵母细胞时特异度85%,有助于提高对获健康胚胎的预测把握。

局限性

  • 本研究为回顾性研究,分析的周期数有限。
  • 纳入新鲜PGT周期的患者基于卵巢储备参数筛选,卵巢储备检测值较高,可能影响结论。
  • 结果仅适用于AMH>1 ng/ml且AFC>10个卵泡的目标人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What are the chances of obtaining a healthy transferable cleavage-stage embryo according to the number of mature oocytes in fragile X mental retardation 1 (FMR1)-mutated or premutated females undergoing preimplantation genetic testing (PGT)? SUMMARY ANSWER: In our population, a cycle with seven or more mature oocytes has an 83% chance of obtaining one or more healthy embryos. WHAT IS KNOWN ALREADY: PGT may be an option to achieve a pregnancy with a healthy baby for FMR1 mutation carriers. In addition, FMR1 premutation is associated with a higher risk of diminished ovarian reserve and premature ovarian failure. The number of metaphase II (MII) oocytes needed to allow the transfer of a healthy embryo following PGT has never been investigated. STUDY DESIGN, SIZE, DURATION: The study is a monocentric retrospective observational study carried out from January 2006 to January 2020 that is associated with a case-control study and that analyzes 38 FMR1 mutation female carriers who are candidates for PGT; 16 carried the FMR1 premutation and 22 had the full FMR1 mutation. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 95 controlled ovarian stimulation (COS) cycles for PGT for fragile X syndrome were analyzed, 49 in premutated patients and 46 in fully mutated women. Only patients aged ≤38 years with anti-Müllerian hormone (AMH) >1 ng/ml and antral follicle count (AFC) >10 follicles were eligible for the PGT procedure. Each COS cycle of the FMR1-PGT group was matched with the COS cycles of partners of males carrying any type of translocation (ratio 1:3). Conditional logistic regression was performed to compare the COS outcomes. We then estimated the number of mature oocytes needed to obtain at least one healthy embryo after PGT using receiver operating characteristic curve analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Overall, in the FMR1-PGT group, the median number of retrieved and mature oocytes per cycle was 11 (interquartile range 7-15) and 9 (6-12), respectively. The COS outcomes of FMR1 premutation or full mutation female carriers were not altered compared with the matched COS cycles in partners of males carrying a balanced translocation in their karyotype. Among the 6 (4-10) Day 3 embryos obtained in the FMR1-PGT group, a median number of 3 (1-6) embryos were morphologically eligible for biopsy, leading to 1 (1-3) healthy embryo. A cutoff value of seven MII oocytes yielded a sensitivity of 82% and a specificity of 61% of having at least one healthy embryo, whereas a cutoff value of 10 MII oocytes led to a specificity of 85% and improved positive predictive value. LIMITATIONS, REASONS FOR CAUTION: This study is retrospective, analyzing a limited number of cycles. Moreover, the patients who were included in a fresh PGT cycle were selected on ovarian reserve parameters and show high values in ovarian reserve tests. This information could influence our conclusion. WIDER IMPLICATIONS OF THE FINDINGS: The results relate only to the target population of this study, with a correct ovarian reserve of AMH >1 and AFC >10. However, the information provided herein extends knowledge about the current state of COS for FMR1 mutation carriers in order to provide patients with proper counseling regarding the optimal number of oocytes needed to have a chance of transferring an unaffected embryo following PGT. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Sonigo C, Mayeur A, Sadoun M, et al. What is the threshold of mature oocytes to obtain at least one healthy transferable cleavage-stage embryo after preimplantation genetic testing for fragile X syndrome? Hum Reprod. 2021. PMID: 34568938. doi:10.1093/humrep/deab214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。